Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.39 |
| ▸ | GABRD | O14764 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.39 |
| ▸ | GABRE | P78334 | 3/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423753 | 0.98 | — | — | |
| SCHEMBL15684113 | 0.98 | — | — | |
| SCHEMBL5729035 | 0.98 | — | — | |
| SCHEMBL16731182 | 0.84 | SLC6A1 (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL39569 | 0.83 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL399574 | 0.78 | — | — | |
| Lithium Ion SCHEMBL1665953 | 0.76 | CA12 (0.33) | — | |
| Hydrochloric Acid SCHEMBL1746024 | 0.75 | — | — | |
| Lithium SCHEMBL8040608 | 0.75 | — | — | |
| SCHEMBL28501013 | 0.74 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221819-B2 | Spirocyclic compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-8877749-B2 | Spirocyclic compounds as modulators of chemokine receptor activity | Bristol-Myers Squibbs Company (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2486034-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202802-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| WO-2011044197-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202802-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CXCR1, CCR7 | GABRP 1290/4885GABRD 1184/4885GABRA1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.